Endometriosis and adenomyosis are chronic, debilitating, inflammatory conditions affecting women of reproductive age. Current management primarily focuses on pharmacologic therapies and surgical interventions; however, many individuals adopt self-directed lifestyle modifications …
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia 2 Minute Medicine
Letrozole and other aromatase inhibitors are increasingly recognized as first-line ovulation induction (OI) medications, offering an efficient and physiologic approach to ovarian stimulation that enhances outcomes in reproductive medicine. By …
Endometriosis (EMs) is a prevalent and challenging gynecological disease and current therapeutic outcomes are suboptimal. Traditional Chinese medicine (TCM) has numerous advantages in treating EMs. Bushen Wenyang Huayu Formula (BWHF), …
Endometriosis (EMs) is an estrogen-dependent, chronic inflammatory disorder characterized by immune microenvironment dysregulation, a critical factor in its pathogenesis. Despite existing therapies, limitations persist, highlighting the urgent need for innovative …
What Medicine Misses When It Refuses to Listen The Good Men Project
This study aims to investigate the differences in response to dienogest (DNG) therapy among patients with 3 different phenotypes of endometriosis: ovarian endometrioma (OMA), superficial peritoneal endometriosis (SUP), and deep …
ENDOx: Reimagining Endometriosis Care Through Precision Nanomedicine Wyss Institute at Harvard
Totus Medicines to Present Updated Phase 1 Clinical Data for TOS-358 at ESMO Targeted Anticancer Therapies Congress 2026 The Manila Times
Endometriosis is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, non-hormonal therapies is urgently needed. We …